Please login or register first to view this content.
Kidney Disease Resource Center
Drug Monographs
Click on the subsection below to see prescribing information
NEWS & FEATURES
Beti-Cel, a Gene Therapy for Beta-Thalassemia, Gets FDA Panel Support
Bristol Myers Squibb Withdraws Luspatercept sBLA for NTD Beta Thalassemia
Methylprednisolone Slows Progression in IgA Nephropathy
Aspirin May Lower Cardiovascular Risks in Chronic Kidney Disease Population
Optimal Difelikefalin Dose Reported for Pruritus in Hemodialysis
Sparsentan Gets Priority Review for IgA Nephropathy
FDA Warns of Potential Chemical Exposure With Certain Hemodialysis Machines
Combining Dapagliflozin and Eplerenone Further Reduces Albuminuria in CKD
Underuse of Diabetic Kidney Disease Therapies Reported
Colchicine May Lower Risk of CKD Progression
FDA to Review Daprodustat for Anemia of Chronic Kidney Disease
Trials Investigating Bempegaldesleukin in Combination With Nivolumab Discontinued
Bevacizumab Biosimilar Alymsys Gets FDA Approval
RAASi Dose Reduction, Discontinuation in CKD Common After Hyperkalemia
Enrollment Paused in Trials Evaluating BCX9930 for Complement-Mediated Diseases
Daprodustat Possibly an Oral Alternative to ESAs in Incident Dialysis
Anaphylaxis Rare With IV Iron Use, But Risk Varies By Formulation
March 2022: Drug Pipeline Updates
